Alector, Inc. ALEC

US Biotechnology

$2.59 ▲ +5.28% (+$0.13)

⬆️ Above Yest. High

Open $2.39

Prev Close $2.46

Day Range $2.39 – $2.64

52W Range $1.09 – $2.76

Market Cap $366.24M

Beta 0.60

EPS (TTM) $-1.09

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-02-07
Shares Out.	148,260,000
Website	alector.com ↗
Phone	13026587581
Employees	103
Revenue	$3.3M
Gross Profit	$3.3M
Net Income	-$23.0M
Free Cash Flow	-$158.4M
Total Assets	$202.9M
Total Liabilities	$212.8M
Equity	-$10.0M

About Alector, Inc.

Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.

Alector, Inc. is a publicly traded company under the ticker symbol ALEC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.